Allogene Therapeutics (Allogene Therapeutics) GF Score : 39/100 (As of May. 12, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Allogene Therapeutics GF Score?

Allogene Therapeutics has the GF Score of 39, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 5/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 8/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Allogene Therapeutics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Allogene Therapeutics's GF Score

For the Biotechnology subindustry, Allogene Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allogene Therapeutics's GF Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allogene Therapeutics's GF Score distribution charts can be found below:

* The bar in red indicates where Allogene Therapeutics's GF Score falls into.

Allogene Therapeutics (NAS:ALLO) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Allogene Therapeutics GF Score Related Terms

Thank you for viewing the detailed overview of Allogene Therapeutics's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Allogene Therapeutics (Allogene Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allogene Therapeutics Inc (NAS:ALLO) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

210 East Grand Avenue, South San Francisco, CA, USA, 94080

Website

https://www.allogene.com

Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

Executives

Deborah M. Messemer	director	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Geoffrey M. Parker	officer: CHIEF FINANCIAL OFFICER	15 RIORDAN PLACE, MENLO PARK CA 94025
Earl Martin Douglas	officer: GENERAL COUNSEL	BIOMIMETIC THERAPEUTICS, INC., 389 NICHOL MILL LANE, FRANKLIN TN 37067
Yinlin Jack Chen	officer: SVP, Finance	210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Stephen Mayo	director	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Timothy L. Moore	officer: Chief Technical Officer	C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Lillian Smith	officer: VP, Corporate Counsel	210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Veer Bhavnagri	officer: General Counsel	C/O ALLOGENE THERAPEUTICS, INC., 210 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Zachary Roberts	officer: EVP of R&D	C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
Owen N. Witte	director	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Rafael Amado	officer: EVP of R&D and CMO	210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Alison Moore	officer: Chief Technical Officer	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Eric Thomas Schmidt	officer: Chief Financial Officer	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
David D Chang	director, officer: President and CEO	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Jon Winkelried	10 percent owner	C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004